Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer
Menée à l'aide de modèles murins et de tissus coliques issus de patients présentant un adénome ou atteints d'un cancer colorectal ou d'une maladie inflammatoire de l'intestin, cette étude démontre que la dérégulation des cellules lymphoïdes innées du groupe 3 favorise la progression tumorale et la résistance des cellules cancéreuses aux immunothérapies
Group 3 innate lymphoid cells (ILC3s) regulate immunity and inflammation, yet their role in cancer remains elusive. Here, we identify that colorectal cancer (CRC) manifests with altered ILC3s that are characterized by reduced frequencies, increased plasticity, and an imbalance with T cells. We evaluated the consequences of these changes in mice and determined that a dialog between ILC3s and T cells via major histocompatibility complex class II (MHCII) is necessary to support colonization with microbiota that subsequently induce type-1 immunity in the intestine and tumor microenvironment. As a result, mice lacking ILC3-specific MHCII develop invasive CRC and resistance to anti-PD-1 immunotherapy. Finally, humans with dysregulated intestinal ILC3s harbor microbiota that fail to induce type-1 immunity and immunotherapy responsiveness when transferred to mice. Collectively, these data define a protective role for ILC3s in cancer and indicate that their inherent disruption in CRC drives dysfunctional adaptive immunity, tumor progression, and immunotherapy resistance.